{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:03:28Z","timestamp":1789628608604,"version":"build-2803163510"},"reference-count":15,"publisher":"Royal College of Psychiatrists","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["BJPsych Bull"],"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Clozapine remains the most effective treatment for treatment-resistant schizophrenia, yet its use is constrained by concerns about safety and preventable adverse outcomes. Evidence on clozapine safety remains fragmented and methodologically heterogeneous, limiting translation into clinical practice. Pharmacovigilance, therapeutic drug monitoring, pharmacokinetics and pharmacogenetics provide complementary information that is rarely considered together. This editorial argues that integrating these approaches within a coherent clinical framework may improve prediction and individualisation of risk while acknowledging current methodological limitations. Progress may therefore depend less on generating additional isolated evidence than on connecting the data already available.<\/jats:p>","DOI":"10.1192\/bjb.2026.10284","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:18:03Z","timestamp":1789625883000},"page":"1-3","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":0,"title":["Integrating pharmacovigilance, pharmacokinetics and clinical outcomes in clozapine safety science"],"prefix":"10.1192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5742-905X","authenticated-orcid":false,"given":"Carlos","family":"De las Cuevas","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01r9z8p25","id-type":"ROR","asserted-by":"publisher"}],"name":"University of La Laguna"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"S2056469426102848_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00519-2"},{"key":"S2056469426102848_ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0448-6"},{"key":"S2056469426102848_ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001747"},{"key":"S2056469426102848_ref4","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16050503"},{"key":"S2056469426102848_ref3","first-page":"357","article-title":"Global economic burden of schizophrenia: a systematic review","volume":"12","author":"Chong","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"S2056469426102848_ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000507638"},{"key":"S2056469426102848_ref7","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sby052"},{"key":"S2056469426102848_ref5","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"S2056469426102848_ref8","first-page":"165","article-title":"Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: comparing the top four reporting countries (US, UK, Canada and Australia)","volume":"268","author":"De las Cuevas","year":"2024","journal-title":"Schizophr Res"},{"key":"S2056469426102848_ref13","doi-asserted-by":"publisher","DOI":"10.1177\/009286150804200501"},{"key":"S2056469426102848_ref14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"S2056469426102848_ref9","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S495254"},{"key":"S2056469426102848_ref15","volume-title":"Causal Inference: What If","author":"Hern\u00e1n","year":"2020"},{"key":"S2056469426102848_ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.1702"},{"key":"S2056469426102848_ref1","volume-title":"Schizophrenia","year":"2025"}],"container-title":["BJPsych Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2056469426102848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:18:04Z","timestamp":1789625884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2056469426102848\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":15,"alternative-id":["S2056469426102848"],"URL":"https:\/\/doi.org\/10.1192\/bjb.2026.10284","relation":{},"ISSN":["2056-4694","2056-4708"],"issn-type":[{"value":"2056-4694","type":"print"},{"value":"2056-4708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"\u00a9 The Author(s), 2026. Published by Cambridge University Press on behalf of Royal College of Psychiatrists","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}